Folger Nolan Fleming Douglas Capital Management Inc. Reduces Stock Holdings in iShares Biotechnology ETF (NASDAQ:IBB)

Folger Nolan Fleming Douglas Capital Management Inc. reduced its holdings in iShares Biotechnology ETF (NASDAQ:IBB) by 3.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 65,386 shares of the financial services provider’s stock after selling 2,444 shares during the period. iShares Biotechnology ETF comprises 1.0% of Folger Nolan Fleming Douglas Capital Management Inc.’s holdings, making the stock its 26th biggest position. Folger Nolan Fleming Douglas Capital Management Inc. owned about 0.12% of iShares Biotechnology ETF worth $8,883,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Jacobi Capital Management LLC raised its position in shares of iShares Biotechnology ETF by 3.7% in the third quarter. Jacobi Capital Management LLC now owns 2,539 shares of the financial services provider’s stock valued at $310,000 after buying an additional 91 shares during the last quarter. PFG Investments LLC raised its position in shares of iShares Biotechnology ETF by 4.8% in the third quarter. PFG Investments LLC now owns 2,013 shares of the financial services provider’s stock valued at $246,000 after buying an additional 93 shares during the last quarter. Huntington National Bank raised its position in shares of iShares Biotechnology ETF by 7.4% in the third quarter. Huntington National Bank now owns 1,450 shares of the financial services provider’s stock valued at $177,000 after buying an additional 100 shares during the last quarter. HB Wealth Management LLC raised its position in shares of iShares Biotechnology ETF by 5.9% in the fourth quarter. HB Wealth Management LLC now owns 1,892 shares of the financial services provider’s stock valued at $257,000 after buying an additional 105 shares during the last quarter. Finally, Peterson Wealth Management raised its position in shares of iShares Biotechnology ETF by 2.9% in the third quarter. Peterson Wealth Management now owns 3,743 shares of the financial services provider’s stock valued at $458,000 after buying an additional 106 shares during the last quarter. 62.45% of the stock is owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Price Performance

Shares of NASDAQ IBB traded up $0.82 during mid-day trading on Friday, reaching $126.49. The company’s stock had a trading volume of 833,050 shares, compared to its average volume of 1,534,186. iShares Biotechnology ETF has a 1-year low of $111.83 and a 1-year high of $141.16. The stock has a 50-day moving average of $134.45 and a two-hundred day moving average of $129.71.

iShares Biotechnology ETF Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, March 27th. Investors of record on Friday, March 22nd were given a dividend of $0.126 per share. This represents a $0.50 annualized dividend and a yield of 0.40%. The ex-dividend date of this dividend was Thursday, March 21st.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.